List of Excipients in Branded Drug LYLLANA

Generic Drugs Containing LYLLANA

Company	Ingredient	NDC	Excipient
Amneal Pharmaceuticals LLC	estradiol	65162-126	DIMETHICONOL/TRIMETHYLSILOXYSILICATE CROSSPOLYMER
Amneal Pharmaceuticals LLC	estradiol	65162-126	DIPROPYLENE GLYCOL
Amneal Pharmaceuticals LLC	estradiol	65162-126	OLEYL ALCOHOL
Amneal Pharmaceuticals LLC	estradiol	65162-126	POVIDONE K30

What are the Most Frequently-Used Excipients in LYLLANA?

# Of NDCs	Excipient
1	DIMETHICONOL/TRIMETHYLSILOXYSILICATE CROSSPOLYMER
1	DIPROPYLENE GLYCOL
1	OLEYL ALCOHOL
1	POVIDONE K30

Lyllana Excipient Strategy and Commercial Opportunities for Estradiol Transdermal Patches

Last updated: September 24, 2026

Lyllana is an estradiol transdermal system marketed by Viatris as a prescription hormone-replacement therapy. Its commercial and technical value depends less on the active ingredient, estradiol, than on adhesive performance, skin permeation, dose uniformity, residual drug, packaging stability, and patient adherence. The principal opportunity is not a new excipient alone. It is a differentiated transdermal platform that improves adhesion, reduces skin irritation, extends wear time, or lowers manufacturing cost while preserving FDA bioequivalence.

What is Lyllana and how is it delivered?

Lyllana delivers estradiol through the skin using a matrix-type transdermal patch. FDA labeling identifies multiple dosage strengths that deliver approximately 0.025, 0.0375, 0.05, 0.075, or 0.1 mg of estradiol per day, depending on the product presentation.[1]

Product attribute	Lyllana profile
Active ingredient	Estradiol
Dosage form	Transdermal system
Route	Transdermal
Therapy area	Menopausal vasomotor symptoms, vulvar and vaginal atrophy, hypoestrogenism, and osteoporosis prevention under labeled conditions
Patch architecture	Backing layer, drug-containing adhesive matrix, release liner
Dosing schedule	Generally twice weekly
Regulatory status	FDA-approved prescription product
Commercial category	Branded or authorized-generic-type estradiol patch segment
Key technical constraint	Controlled delivery through skin with reliable adhesion and low irritation

The patch is designed to maintain systemic estradiol exposure while avoiding first-pass hepatic metabolism associated with oral administration. The formulation must control drug release over the intended wear period and maintain adhesion under heat, moisture, movement, and friction.[1]

What excipients are used in Lyllana?

The Lyllana transdermal system uses a multilayer construction. FDA labeling identifies the drug-containing adhesive matrix as containing acrylic adhesive, silicone adhesive, oleic acid, povidone, dipropylene glycol, and ethanol.[1]

Lyllana excipient functions

Excipient or component	Primary technical function	Commercial significance
Acrylic adhesive	Provides pressure-sensitive adhesion and may contribute to drug release	Controls wear time, tack, peel strength, and skin compatibility
Silicone adhesive	Improves adhesion and flexibility; can modify drug partitioning	May reduce dependence on a single adhesive chemistry
Oleic acid	Permeation enhancer and lipid-compatible excipient	Increases estradiol transport through the stratum corneum
Povidone	Solubilizer, polymeric stabilizer, or matrix modifier	Can influence drug dispersion and crystallization risk
Dipropylene glycol	Solvent, humectant, and formulation modifier	Affects drug mobility and matrix plasticity
Ethanol	Volatile solvent and processing aid	Supports initial solubilization but requires control of residual solvent and evaporation
Backing film	Protects the matrix and controls environmental exposure	Affects occlusion, flexibility, moisture transmission, and package stability
Release liner	Protects the adhesive before application	Influences peel performance, die-cutting, and user handling

The exact performance of the patch depends on the combination of excipients rather than the individual materials. Estradiol is a potent, low-dose molecule. Small changes in solubility, crystallization, adhesive microstructure, or skin permeation can alter delivered dose.

How does the Lyllana formulation control estradiol delivery?

Estradiol transdermal systems must maintain the active ingredient in a sufficiently mobile and skin-permeable state while preventing uncontrolled release. The formulation generally operates through four mechanisms.

First, the adhesive matrix holds the drug against the skin. Second, oleic acid and solvent components modify the stratum corneum and support drug partitioning. Third, acrylic and silicone adhesive domains regulate drug diffusion and patch retention. Fourth, the backing layer limits mechanical and environmental disruption.

A commercial formulation must control:

• Estradiol content uniformity across the patch web
• Drug crystallization during storage
• Adhesive cold flow
• Peel and tack after aging
• Skin irritation and sensitization
• Residual solvent levels
• Drug loss into the release liner
• Drug transfer to clothing or caregivers
• Wear performance after bathing and sweating
• Dose delivery over the full labeled interval

The most important development risk is a tradeoff between permeability and tolerability. Increasing oleic acid or solvent content can improve flux but may increase erythema, burning, or variability across patients.

What excipient strategies could improve on Lyllana?

Lower-irritation adhesive systems

A commercial developer could replace or rebalance the acrylic-silicone adhesive system to reduce skin reactions. Candidate approaches include:

• Silicone-dominant adhesives for sensitive skin
• Lower-monomer acrylic systems
• Hypoallergenic crosslinked adhesives
• Reduced enhancer concentrations
• Adhesive systems with lower residual monomer and extractables profiles

The regulatory burden is substantial because an adhesive change can affect adhesion, estradiol flux, residual drug, and systemic exposure. A change that appears minor from a materials perspective may require comparative in vitro release, skin permeation, adhesion, irritation, stability, and clinical pharmacokinetic data.

Longer-wear patches

Lyllana uses a twice-weekly schedule. A patch designed for seven-day wear could create a meaningful commercial distinction, but the formulation and device would need to maintain:

• Stable estradiol delivery for the full interval
• Adhesion through showering and exercise
• Low edge lift
• Low skin irritation after prolonged occlusion
• Consistent delivery despite declining drug concentration in the matrix

A weekly patch could support adherence and reduce application frequency. Its development risk is higher because cumulative skin exposure, adhesive aging on the body, and late-interval dose control require extensive testing.

Improved skin tolerability

Skin tolerability is a practical barrier to repeat use. Opportunities include lower-occlusion backings, breathable films, lower-residue adhesives, and excipient systems that reduce enhancer-driven irritation.

A differentiated product could target patients who discontinue estradiol patches because of redness, itching, residue, or poor adhesion. The commercial claim would need support from controlled tolerability data, not only laboratory measurements.

Reduced visible residue and easier removal

Patients may value a patch that leaves less adhesive residue or can be removed without tearing. Silicone adhesives can have favorable removal characteristics, while acrylic systems can provide stronger initial tack. A hybrid system could optimize both properties, but the formulation must preserve estradiol release and patch integrity.

Smaller patch area

A higher-flux formulation could reduce patch size while maintaining the same estradiol delivery rate. This would require careful control of enhancer concentration and skin permeation. Smaller patches may improve discretion and comfort, but a higher drug flux can increase interpatient variability and irritation.

What regulatory pathway applies to an improved Lyllana-type patch?

A new estradiol transdermal patch may be pursued through several FDA pathways depending on the level of formulation and device change.

Development approach	Likely regulatory route	Commercial implication
Same active ingredient, dosage form, strength, and intended use	Abbreviated New Drug Application if pharmaceutical equivalence and bioequivalence can be demonstrated	Lower development cost; limited differentiation
Different excipient system with same reference product	ANDA if FDA accepts equivalence strategy; otherwise additional clinical or in vitro support may be needed	Potential generic or authorized-generic positioning
New delivery profile or weekly dosing	505(b)(2) application is more likely	Greater differentiation, higher clinical and regulatory cost
New indication or materially different clinical use	505(b)(2) or full NDA	Larger market opportunity, longer development cycle
New patch device with drug-device integration	NDA, 505(b)(2), or combination-product review depending on the product	Device manufacturing and human-factors requirements increase

FDA guidance for transdermal and topical delivery systems emphasizes product quality, adhesive performance, in vitro release, skin permeation, residual drug, extractables and leachables, and stability.[2] A developer cannot assume that systemic pharmacokinetic similarity alone will resolve all product-quality questions.

What Orange Book and patent issues affect Lyllana?

Lyllana is an FDA-approved estradiol transdermal product listed in FDA drug databases and prescription-drug labeling systems.[1,3] Orange Book analysis should distinguish between:

1. FDA approval status;
2. therapeutic-equivalence coding;
3. listed patents, if any;
4. pediatric-exclusivity information;
5. product-specific labeling and dosage strengths.

A patent search must cover more than the Lyllana brand name. Relevant claims may include:

• Estradiol transdermal matrices
• Acrylic-silicone adhesive combinations
• Permeation-enhancer systems
• Patch geometry and multilayer construction
• Drug crystallization control
• Long-wear delivery
• Manufacturing and coating processes
• Methods of treating menopausal symptoms

Older estradiol patch patents and broad transdermal delivery patents may have expired, but active secondary patents can still affect a new formulation. Patent clearance should therefore examine claims directed to excipient ratios, adhesive chemistry, patch dimensions, release profiles, and manufacturing methods. FDA approval does not itself establish freedom to operate.

What generic entry risks exist for Lyllana?

The main generic-entry routes are conventional ANDA products that match Lyllana or another reference estradiol patch. The most material barriers are technical rather than chemical.

Key generic risks

• Failure to match estradiol delivery over the full application interval
• Adhesion failure during wear testing
• Skin irritation or sensitization
• Drug crystallization during stability studies
• Patch-to-patch variability
• Residual drug differences affecting bioequivalence
• Release-liner interaction
• Packaging-related solvent or moisture migration
• Manufacturing scale-up failures

Estradiol patches are difficult to copy precisely because the adhesive matrix is both the dosage form and the delivery-control system. A generic can use different excipients only if the resulting product satisfies FDA equivalence and quality requirements.

Paragraph IV challenges are possible where listed patents remain relevant. The commercial risk depends on the patent claims, certification timing, litigation outcome, and whether the challenger seeks a launch before patent expiry. Generic competition can also arise from products referencing other estradiol patches rather than Lyllana specifically.

Which companies compete in the estradiol patch market?

The competitive set includes branded and generic transdermal estradiol products marketed by companies such as Viatris, Sandoz, Noven Pharmaceuticals, Bayer, and other generic manufacturers, depending on market and time period. Products may reference different historical brands, including Vivelle-Dot and Climara, and may use different patch sizes, wear schedules, adhesive systems, or manufacturing platforms.[3]

Competitive dimension	Lyllana position	Opportunity for a challenger
Dosing frequency	Twice weekly	Weekly or more flexible dosing
Delivery route	Transdermal	Same route with improved usability
Active ingredient	Estradiol	Same active ingredient is expected
Differentiation	Conventional patch attributes	Better adhesion, lower irritation, smaller size
Regulatory strategy	Existing approved product	ANDA for price competition or 505(b)(2) for innovation
Manufacturing barrier	Coated adhesive matrix and converting	Process know-how and scale reliability
Commercial buyer	Pharmacies, plans, prescribers, patients	Formulary savings or adherence-based value proposition

What licensing opportunities exist for Lyllana-related excipients?

The strongest licensing opportunities are platform-based rather than Lyllana-specific. Potential assets include:

• Hypoallergenic pressure-sensitive adhesive technology
• High-flux, low-irritation permeation-enhancer systems
• Weekly estradiol patch technology
• Breathable backing films
• Low-residue removal systems
• Continuous coating and solvent-recovery processes
• In-line imaging for drug-content uniformity
• Patch packaging that limits moisture and solvent migration

An excipient supplier could license a proprietary adhesive or enhancer system to a generic manufacturer under a formulation-development agreement. The commercial structure could include an upfront payment, development milestones, manufacturing supply commitments, and royalties tied to net sales.

The strongest negotiating position would come from data showing that the excipient system improves a measurable product attribute without increasing regulatory complexity. Useful evidence includes comparative adhesion, irritation, in vitro release, skin permeation, accelerated stability, and pilot-scale coating data.

How strong is the commercial opportunity?

The market opportunity is strongest in three segments:

1. Low-cost generic estradiol patches with reliable supply.
2. Premium patches for patients with adhesion or irritation problems.
3. Lower-frequency products that improve persistence and reduce application burden.

A pure excipient substitution is unlikely to command a large premium unless it produces a clinically visible benefit. A reformulated patch with lower irritation, longer wear, or smaller size has a clearer commercial position.

Manufacturing economics are also important. Estradiol is used at low loading, so the major cost drivers are adhesive materials, coating yield, converting loss, packaging, quality testing, and supply reliability. A formulation that reduces solvent use, increases coating speed, lowers scrap, or improves release-liner yield may generate more value than a costly novel enhancer.

Key Takeaways

• Lyllana is an estradiol matrix transdermal system with multiple strengths and twice-weekly administration.
• Its labeled adhesive matrix includes acrylic adhesive, silicone adhesive, oleic acid, povidone, dipropylene glycol, and ethanol.[1]
• The main formulation opportunities are improved adhesion, lower irritation, reduced residue, smaller patch size, and longer wear.
• Excipient changes can affect drug release, skin permeation, bioequivalence, stability, and regulatory classification.
• An ANDA is the likely route for a close generic copy; a 505(b)(2) application is more suitable for a materially differentiated patch.
• Patent clearance must cover formulation, adhesive, enhancer, patch architecture, method-of-use, and manufacturing claims.
• The most defensible commercial assets are excipient platforms supported by comparative performance data.
• Generic competition is technically constrained by adhesion, skin tolerability, crystallization, and manufacturing scale-up.
• A weekly or lower-irritation estradiol patch could command greater commercial differentiation than an undifferentiated excipient substitution.

FAQs About Lyllana Excipients and Commercial Strategy

Can oleic acid in Lyllana be replaced with another permeation enhancer?

Yes, but the replacement can change estradiol flux, irritation, stability, and bioequivalence. Candidate enhancers require comparative permeation and product-performance testing.

Is the Lyllana adhesive matrix separately patentable?

A new adhesive matrix may be patentable if its composition, performance, or manufacturing process is novel and non-obvious. Existing broad transdermal and estradiol-patch claims must be cleared first.

Would a weekly Lyllana patch require a new clinical program?

A weekly patch would usually require more than routine generic testing because the dosing interval, exposure profile, adhesion period, and patient-use characteristics would differ from the twice-weekly product.

Which excipient is most commercially important in Lyllana?

The adhesive system is the most commercially important because it controls adhesion, drug mobility, skin contact, removal, and part of the release profile. Oleic acid is also important because it affects permeation.

Can a manufacturer market a lower-irritation estradiol patch as therapeutically superior?

Only if the product’s labeling and promotional claims are supported by the applicable FDA pathway and adequate comparative evidence. A lower-irritation claim generally requires controlled tolerability data.

References

1. U.S. Food and Drug Administration. (n.d.). Lyllana (estradiol transdermal system) prescribing information. DailyMed.
2. U.S. Food and Drug Administration. (2019). Transdermal and topical delivery systems: Product development and quality considerations: Guidance for industry.
3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. Orange Book.